Skip to contentS
Starling Oncology, Inc.
S
STLNStarling Oncology, Inc. Q3 2025 · 10-Q
Revenue$136.56M$136.56M+36.7% vs Q3 2024 Net Income-$16.50M-$16.50MN/M vs Q3 2024 EPS Diluted-$0.14-$0.14N/M vs Q3 2024 Operating Income-$8,054,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Starling Oncology, Inc. · CIK 1799191 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$13,234,000N/M Margins · derivedOperating margin-5.9%+8.0 pt vs Q3 2024
Net margin-12.1%+4.0 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 13, 2025 · 44 d after period end